Mevacor, Other Statins To Be Considered By California Carcinogen Committee
Executive Summary
California's Carcinogen Identification Committee will evaluate during its Dec. 17 meeting whether all statins should be designated as carcinogens under Proposition 65, rather than Merck's Mevacor (lovastatin) alone
You may also be interested in...
Statins under California Prop 65
California's Office of Environmental Health Hazard Assessment should assess toxicological studies on each member of the statin class of cholesterol drugs, California Carcinogen Committee recommended at Dec. 17 meeting. OEHHA will present to committee on consideration of each drug for placement on Proposition 65 carcinogen list at 2003 or 2004 annual meeting. Merck's Mevacor (lovastatin) was picked for consideration at random, but Merck petitioned committee to consider the statins as a group (1"The Pink Sheet" Dec. 9, 2002, p. 22)...
Statins under California Prop 65
California's Office of Environmental Health Hazard Assessment should assess toxicological studies on each member of the statin class of cholesterol drugs, California Carcinogen Committee recommended at Dec. 17 meeting. OEHHA will present to committee on consideration of each drug for placement on Proposition 65 carcinogen list at 2003 or 2004 annual meeting. Merck's Mevacor (lovastatin) was picked for consideration at random, but Merck petitioned committee to consider the statins as a group (1"The Pink Sheet" Dec. 9, 2002, p. 22)...
FDA Drug Ad Rulings Do Not Need To Rely On Consumer Survey Data – Troy
FDA decisions on whether direct-to-consumer drug ads are false or misleading do not need to be backed with consumer comprehension data, Chief Counsel Daniel Troy said